Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo gets tentative FDA ok for lopinavir/ritonavir

This article was originally published in Scrip

Executive Summary

Aurobindo Pharma has received tentative US FDA approval for lopinavir/ritonavir tablets 100/25mg and 200/50mg, generic versions of Abbott Laboratories' antiretroviral Kaletra tablets. This is the first tentative approval of a generic version of Kaletra under PEPFAR (President's Emergency Plan for AIDS Relief). Aurobindo, which recently entered a licensing and supply deal with Pfizer for a range of generics (scripnews.com, March 4th, 2009), now has 93 ANDA approvals (66 final and 27 tentative approvals) from the FDA.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000774

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel